Compare BMEA & FURY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | FURY |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 111.2M |
| IPO Year | 2021 | 2011 |
| Metric | BMEA | FURY |
|---|---|---|
| Price | $1.40 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $9.83 | $1.70 |
| AVG Volume (30 Days) | ★ 1.2M | 296.0K |
| Earning Date | 05-12-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.45 |
| 52 Week High | $3.07 | $1.02 |
| Indicator | BMEA | FURY |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 42.47 |
| Support Level | $1.23 | $0.51 |
| Resistance Level | $1.45 | $0.63 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 47.57 | 13.68 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.